Your analysis regarding the excessive money and time to market wasted by the drug companies is generally on target. The only point where I feel a qualifier is needed is about the documents’ information not necessarily being accurate.

While there is an accuracy issue–granted–it is also true that pharma and biotech companies perform internal audits and are subject to external audits throughout the drug discovery and clinical development processes. Audits can include discovery data in lab notebooks, clinical research data from human studies, and even the resumes of contractors who work on a project.

All that being said, I do agree with you that even minor process improvements, especially in drug development, could speed drugs to market faster, cutrting costs along the way.

Dr Susan E Caldwell

President and Writing Consultant

Biotech Ink, LLC—the Contract Writing OrganizationSM

Foster City, CA

Tel:  650-286-9300

Web: http://www.biotechink.com